Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Head and Neck Cancer Registry (LORHAN)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01080313
First received: March 2, 2010
Last updated: February 10, 2012
Last verified: February 2012

March 2, 2010
February 10, 2012
August 2005
December 2011   (final data collection date for primary outcome measure)
Patterns of care for head and neck cancer [ Time Frame: up to 10 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01080313 on ClinicalTrials.gov Archive Site
  • Overall survival by treatment regimen [ Time Frame: study entry to death from any cause or to end of study ] [ Designated as safety issue: No ]
  • Determine the incidence and severity of major dose-limiting and other important treatment toxicities [ Time Frame: up to 10 years ] [ Designated as safety issue: Yes ]
  • Identify supportive care received for managing nutrition, pain, nausea and other complications [ Time Frame: up to 10 years ] [ Designated as safety issue: No ]
  • tumor control by treatment regimen [ Time Frame: study entry to progressive disease ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Head and Neck Cancer Registry (LORHAN)
Prospective, Longitudinal, Multi-Center, Descriptive Registry of Patients Receiving Therapy Other Than Surgical Resection Alone for Newly Diagnosed Head and Neck Cancer

The primary objective of this study is to describe, in detail, patterns of care for head and neck carcinoma patient

Not Provided
Observational
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Primary care clinic

Head and Neck Cancer
Other: Therapy for head and neck cancer
radiotherapy and/or drug therapy including chemotherapy, biologic therapy and targeted therapy
Patients with head and neck cancer
Intervention: Other: Therapy for head and neck cancer
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
26000
December 2011
December 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Pathologically (histologically or cytologically) confirmed new diagnosis of carcinoma involving the oral cavity, oropharynx, nasopharynx, hypopharynx, larynx, or neck node metastasis from unknown origin
  • Scheduled to receive radiotherapy and/or drug therapy including chemotherapy, biologic therapy and targeted therapy
  • Written informed consent

Exclusion Criteria:

  • Registry participation does not exclude participation in clinical trials.
  • Patients scheduled to receive or who have received surgery are eligible for Registry participation as long as they are also scheduled to receive medical therapy.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01080313
13440, I4E-US-S003
No
Eli Lilly and Company
Eli Lilly and Company
Not Provided
Study Director: Mednet Solutions Mednet Solutions
Eli Lilly and Company
February 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP